Prediction of Metastatic Disease and Survival in Patients with Gastric and Gastroesophageal Junction Tumors. The Incremental Value of PET-CT over PET and the Clinical Role of Primary Tumor Volume Measurements

Academic Radiology

Volumn 16, Issue 2, 2009, Pages 218-226

  Roedl, Johannes B ^a   Prabhakar, Hima B ^a   Mueller, Peter R ^a   Colen, Rivka R ^a   Blake, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

computed tomography; Esophageal carcinoma; metastasis; positron emission tomography; tumor volume

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINATED CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ESOPHAGUS CARCINOMA; ESOPHAGUS TUMOR; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; STOMACH TUMOR; TUMOR VOLUME;

AGED; CARCINOMA; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; INCIDENCE; MALE; MASSACHUSETTS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 58049191022     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2008.06.004     Document Type: Article

References (21)

1. Siewert J.R., and Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85 (1998) 1457-1459
2. Botterweck A.A., Schouten L.J., Volovics A., et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29 (2000) 645-654
3. Devesa S.S., Blot W.J., and Fraumeni Jr. F.J. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
4. Ellis Jr. F.H., Heatley G.J., Krasna M.J., et al. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 113 (1997) 836-846
5. Lagarde S.M., ten Kate F.J., Reitsma J.B., et al. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 24 (2006) 4347-4355
6. Rice T.W., Blackstone E.H., Adelstein D.J., et al. Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma. J Thorac Cardiovasc Surg 125 (2003) 1091-1102
7. Hong R., Halama J., Bova D., et al. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys 67 (2007) 720-726
8. Leong T., Everitt C., Yuen K., et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol 78 (2006) 254-261
9. Nestle U., Kremp S., Schaefer-Schuler A., et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 46 (2005) 1342-1348
10. Konski A., Doss M., Milestone B., et al. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 1123-1128
11. Bruzzi F., Swisher S.G., Truong M.T., et al. Detection of interval distant metastases. Clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 109 (2007) 125-134
12. Cerfolio R.J., Bryant A.S., Ohja B., et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 129 (2005) 1232-1241
13. Reed C.E. Surgical management of esophageal carcinoma. Oncologist 4 (1999) 95-105
14. Flamen P., Lerut A., Van Cutsem E., et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18 (2000) 3202-3210
15. Heeren P.A., Jager P.L., Bongaerts F., et al. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 45 (2004) 980-987
16. Liberale G., Van Laethem J.L., Gay F., et al. The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol 30 (2004) 942-947
17. Meltzer C.C., Luketich J.D., Friedman D., et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 25 (2000) 882-887
18. McAteer D., Wallis F., Couper G., et al. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 72 (1999) 525-529
19. Kole A., Plukker J., Nieweg O., et al. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 78 (1998) 521-527
20. van Westreenen H.L., Westerterp M., Bossuyt P.M., et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22 (2004) 3805-3812
21. Jadvar H., Henderson R.W., and Conti P.S. 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol 8 (2006) 193-200